OncoMatch/Clinical Trials/NCT07270835
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Is NCT07270835 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Rituximab and Zanubrutinib for hemophagocytic lymphohistiocytosis.
Treatment: Rituximab · Zanubrutinib — For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 CD20-positive (increased proportion of CD20-positive B cells by bone marrow flow cytometry)
HLH patients whose bone marrow flow cytometry show an increased proportion of CD20-positive B cells
Prior therapy
Cannot have received: experimental drugs
Exception: had not completed the drug washout period
Have received other experimental drugs and had not completed the drug washout period
Lab requirements
Blood counts
Fibrinogen could be corrected to ≥0.6g/L by infusion
Kidney function
Baseline serum creatinine ≤1.5 times ULN; CrCl <30 mL/min or severe renal insufficiency [excluded]
Liver function
ALT or AST >5 times the upper limit, or severe cirrhosis [excluded]
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography; NYHA class III-IV heart failure or severe arrhythmia [excluded]
Baseline serum creatinine ≤1.5 times ULN; Fibrinogen could be corrected to ≥0.6g/L by infusion; Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography; Severe organ dysfunction including NYHA class III-IV heart failure or severe arrhythmia; Liver function: ALT or AST >5 times the upper limit, or severe cirrhosis; Renal function: CrCl <30 mL/min or severe renal insufficiency
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify